Animal Model Market Size & Growth Forecast 2027–2036, By Segments (End-use, Application Scope, Animal Type Scope), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Animal Model Market size was estimated at USD 2.8 billion in 2026 and is projected to grow at a 9.12% CAGR from 2027 to 2036, exceeding USD 6.7 billion by 2036. The industry revenue for 2027 is calculated at USD 3.02 billion.
Get more details on this report
Request Free Sample ReportAnimal Model Market Intelligence Snapshot
Regional Market Dynamics
- North America holds a 51.08% share due to its mature biomedical research ecosystem, strong funding, and extensive use of animal models in drug discovery and preclinical testing.
- Asia Pacific is growing at a 9.94% CAGR driven by expanding life sciences research capacity, rising pharmaceutical activity, and increasing adoption of standardized preclinical testing systems.
Segment Momentum
- Pharmaceutical & Biotechnology Companies held a 41.34% share in 2026 because they require animal models across drug discovery, preclinical validation, and pipeline development while maintaining in-house control over research execution and data continuity.
- Contract Research Organizations are growing fastest as sponsors seek cost-efficient, flexible preclinical research support, helping reduce timelines and access specialized study capabilities without expanding internal infrastructure.
Market Expansion Drivers
- Rising biopharmaceutical R&D activity increasing reliance on animal models for preclinical drug validation.
- Growth of oncology and genetic research expanding use of mice-based experimental models.
- Expansion of CRISPR and advanced gene-editing technologies enhancing translational research models.
Leading Market Participants
- Leading players in the animal model market include Charles River Laboratories International, Inc. (United States), The Jackson Laboratory (United States), Taconic Biosciences, Inc. (United States), genOway S.A. (France), Janvier Labs (France), Crown Bioscience Inc. (United States), Inotiv, Inc. (United States), Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (China), Envigo RMS LLC (United States), Harbour BioMed Ltd. (China).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.8 billion
- 2027 Estimated Market Size: USD 3.02 billion.
- Projected Market Size: USD 6.7 billion by 2036
- Growth Forecast: 9.12% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Pharmaceutical & Biotechnology Companies (End-use) | Cancer (Application Scope) | Mice (Animal Type Scope)
- Emerging Opportunity Segment: Contract Research Organization (End-use) | Cancer (Application Scope) | Mice (Animal Type Scope)
Market Growth Drivers and Industry Trends
Rising biopharmaceutical R&D activity increasing reliance on animal models for preclinical drug validation
Rising biopharmaceutical research and development activity will propel the animal model market as drug developers require established preclinical systems to evaluate safety, efficacy, pharmacological responses, and disease mechanisms before advancing candidates into human studies. Animal models provide researchers with biological systems for studying therapeutic effects and potential risks under controlled experimental conditions. Increasing development activity across pharmaceuticals and biologics is therefore sustaining demand for validated models that can support different stages of preclinical research and candidate assessment.
Growth of oncology and genetic research expanding use of mice-based experimental models
The expansion of oncology and genetic research is strengthening the animal model market, particularly through increased use of mice-based experimental systems for studying disease mechanisms and therapeutic responses. Mice can be used to investigate tumor development, genetic alterations, immune responses, and treatment outcomes in controlled research settings. Their established role in laboratory research and the availability of models with specific genetic characteristics enable researchers to examine complex biological pathways and evaluate potential interventions across a broad range of cancer and genetic studies.
Expansion of CRISPR and advanced gene-editing technologies enhancing translational research models
The expansion of CRISPR and other advanced gene-editing technologies is creating new capabilities within the animal model market by enabling researchers to develop models with targeted genetic modifications that more closely represent specific biological conditions. Gene-editing tools allow researchers to alter selected genes and investigate their roles in disease development, therapeutic response, and biological processes. Such precision supports the creation of specialized experimental models for translational research, allowing preclinical studies to examine disease mechanisms and potential treatments within more relevant biological contexts.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising biopharmaceutical R&D activity increasing reliance on animal models for preclinical drug validation | 2.40% | High | North America, Europe | High | Near Term |
| Growth of oncology and genetic research expanding use of mice-based experimental models | 2.10% | High | North America, Asia Pacific | High | Near Term |
| Expansion of CRISPR and advanced gene-editing technologies enhancing translational research models | 1.70% | High | North America, Europe, Asia Pacific | Emerging | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The animal model market was led by North America, which accounted for a 51.08% share in 2026. The region benefits from a mature biomedical research ecosystem, extensive pharmaceutical and biotechnology activity, and strong demand for preclinical research models. Continued investment in drug discovery, disease research, and therapeutic development supports the use of animal models for evaluating safety and efficacy. Advanced research infrastructure and established scientific capabilities further reinforce the region’s leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, supported by expanding pharmaceutical and biotechnology research, increasing investments in life sciences infrastructure, and the growing need for preclinical testing capabilities. Rising research activity across emerging economies is encouraging broader adoption of animal models in drug development and disease studies. Improvements in laboratory infrastructure, increasing domestic research capacity, and expanding clinical and pharmaceutical development ecosystems are also contributing to the region’s accelerating market growth.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Research ModelsGermany prioritizes high-quality animal models that support biomedical innovation, drug discovery, and translational research. Research institutions and commercial providers in Germany continue refining specialized models while emphasizing reproducibility, ethical practices, and regulatory compliance.
France 🇫🇷
Preclinical Innovation PlatformFrance supports its animal model market through collaborative biomedical research and pharmaceutical innovation initiatives. Research facilities in France continue improving specialized model availability and laboratory capabilities to facilitate efficient preclinical studies across diverse therapeutic areas.
Italy 🇮🇹
Academic Research CollaborationItaly strengthens the animal model market through collaboration between research institutes, universities, and life science organizations. Scientific teams in Italy continue adopting specialized disease models and standardized research protocols that enhance the quality and consistency of preclinical investigations.
Japan 🇯🇵
Advanced Disease ModelingJapan continues advancing the animal model market through sophisticated disease research and precision biomedical studies. Research organizations in Japan emphasize genetically modified models and standardized laboratory practices that strengthen pharmaceutical and life science development programs.
South Korea 🇰🇷
Biotechnology Research SupportSouth Korea is expanding the application of animal models across biotechnology, pharmaceutical development, and academic research. Institutions in South Korea invest in specialized research capabilities and modern laboratory infrastructure to support increasingly complex preclinical evaluation requirements.
United States 🇺🇸
Translational Research CapacityThe U.S. animal model market is supported by extensive biomedical research, pharmaceutical development, and preclinical testing activities. Organizations in the U.S. continue investing in advanced disease models, genetically engineered strains, and specialized research services that improve translational study outcomes.
Segment Leadership and Growth Trends
Animal Model Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs Contract Research Organization (Fastest-Growing Segment)
Pharmaceutical & biotechnology companies represented a 41.34% share of the animal model market in 2026, reflecting their extensive reliance on preclinical research for drug discovery, safety assessment, disease modeling, and therapeutic development. Animal models enable researchers to evaluate biological responses and investigate treatment candidates before progression into human studies. Continued investment in pharmaceutical research and the need for robust preclinical evidence support sustained utilization among these organizations.
Contract research organizations are experiencing faster growth as pharmaceutical and biotechnology developers increasingly rely on external research capabilities to access specialized expertise, facilities, and animal-testing infrastructure. Outsourcing can improve research flexibility while allowing developers to manage complex preclinical programs without maintaining all capabilities internally. Increasing demand for efficient drug development workflows and specialized research services is strengthening the role of CROs in animal model applications.
Application Scope Segment Analysis: Cancer (Largest & Fastest-Growing Segment)
Cancer represented a 49.56% share of the animal model market in 2026 and remained the largest and fastest-growing application scope, reflecting the extensive use of animal models in oncology research. These models support investigation of tumor biology, disease progression, therapeutic mechanisms, and treatment responses, enabling researchers to evaluate potential interventions under controlled biological conditions. Continued emphasis on developing targeted and effective cancer therapies sustains demand for relevant preclinical models across pharmaceutical and biotechnology research.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Pharmaceutical & Biotechnology Companies, Academic Research Institute, Contract Research Organization | Pharmaceutical & Biotechnology Companies | Contract Research Organization |
| Application Scope | Cancer, Immunological Disease, Infectious Disease, Others | Cancer | Cancer |
| Animal Type Scope | Mice, Rat, Guinea Pigs, Rabbits, Hamsters, Others | Mice | Mice |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Key companies in the animal model market:
1. Charles River Laboratories International Inc. (United States)
2. The Jackson Laboratory (United States)
3. Taconic Biosciences Inc. (United States)
4. genOway S.A. (France)
5. Janvier Labs (France)
6. Crown Bioscience Inc. (United States)
7. Inotiv Inc. (United States)
8. Biocytogen Pharmaceuticals (Beijing) Co. Ltd. (China)
9. Envigo RMS LLC (United States)
10. Harbour BioMed Ltd. (China)
Advancements in precision research techniques are significantly shaping the animal model market, with organizations emphasizing the development of highly specialized disease models for therapeutic research. Increased investment in genetic engineering technologies and personalized medicine applications is driving innovation across preclinical testing environments. Additionally, expanded research collaborations and laboratory infrastructure upgrades are improving the availability and diversity of advanced animal model solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. (United States) | |||||||
| The Jackson Laboratory (United States) | |||||||
| Taconic Biosciences Inc. (United States) | |||||||
| genOway S.A. (France) | |||||||
| Janvier Labs (France) | |||||||
| Crown Bioscience Inc. (United States) | |||||||
| Inotiv Inc. (United States) | |||||||
| Biocytogen Pharmaceuticals (Beijing) Co. Ltd. (China) | |||||||
| Envigo RMS LLC (United States) | |||||||
| Harbour BioMed Ltd. (China). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Atelerix | Dec-25 | Atelerix entered a collaborative agreement with Cherry Biotech to integrate its hydrogel preservation technology with advanced organoid research workflows. By facilitating the storage and transport of complex biological models, this partnership improves the efficiency of preclinical handling and supports the scaling of alternative, non-animal-based model systems in biomedical research. |
| China National Macaque Biobank | Oct-25 | The establishment of China's first national macaque biobank, following the analysis of nearly 1,000 subjects, significantly enhances the availability of standardized non-human primate (NHP) resources. This infrastructure project improves the precision and reliability of disease modeling for complex biomedical applications, representing a major regional expansion in high-tier preclinical research capabilities. |
| Taconic Biosciences | Aug-25 | Taconic Biosciences and Cyagen established a strategic partnership across North America and Europe to consolidate access to a library of over 16,000 genetically engineered mouse and rat models. This collaboration streamlines the supply chain for preclinical research, enabling faster procurement of standardized biological models to accelerate drug discovery and development timelines. |
| Applied StemCell | Feb-25 | Applied StemCell reported technical advancements in its proprietary TARGATT gene-editing platform, broadening its utility for generating complex, genetically engineered animal models. These upgrades enhance the platform’s commercial viability for contract research and internal product development, providing researchers with more precise tools to study gene function and disease pathology in preclinical environments. |
| Recombinetics | Nov-24 | Recombinetics, a developer of gene-edited livestock models, filed for bankruptcy protection amid significant financial liabilities. This exit marks a contraction in the specialized market for agricultural-based animal models, illustrating the high capital intensity and commercial challenges inherent in scaling advanced genetic engineering technologies for commercial and research-driven applications. |
| Parallel Bio | Aug-24 | Parallel Bio commercialized a human immune system platform designed as a direct substitute for traditional in vivo animal testing. By enabling the evaluation of immunotherapies within human-based model systems, the company provides a technological alternative that competes with traditional animal-model workflows, reflecting shifting industry demand toward human-centric preclinical diagnostic tools. |
| Cemib | Jan-24 | Cemib inaugurated a new production facility featuring upgraded technological infrastructure for the generation of genetically modified laboratory animals. This expansion increases regional production capacity and operational bandwidth for the provision of sophisticated animal models, supporting the growing demand for specialized research tools required in advanced pharmaceutical and biotechnological product development. |
| Taconic Biosciences | Nov-22 | Avista Capital Partners completed the acquisition of Taconic Biosciences, integrating the firm into its healthcare portfolio. The transaction provided the necessary capital and strategic resources to accelerate the expansion of Taconic’s genetically engineered rodent model (GEM) portfolio and associated preclinical services, reinforcing its competitive position in the global laboratory animal market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Animal Model Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Model Development Approach | Spontaneous Models, Induced Models, Genetically Engineered Models, Transplanted & Xenograft Models |
| Research Stage | Discovery Research, Preclinical Efficacy & Safety Testing, Translational Research, Regulatory Testing |
| Model Standardization | Conventional Models, Specific-Pathogen-Free Models, Germ-Free & Gnotobiotic Models, Humanized Models |
Animal Model Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Preclinical Research Pipeline Opportunity Assessment |
|
| Alternative Testing Methods Impact Analysis |
|
| Outsourcing & CRO Partnership Landscape |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the animal model market?
How much is the animal model industry expected to grow by 2036?
How are advances in gene-editing technologies reshaping procurement in the animal model market?
What is driving increased investment in specialized animal models for preclinical research?
Why do Pharmaceutical & Biotechnology Companies account for the largest share of the animal model market?
Why are Contract Research Organizations the fastest-growing end-use segment in the animal model market?
Why does North America dominate the animal model market?
What factors are accelerating Asia Pacific’s animal model market growth?
Who are the leading players in the animal model landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization